Recent Updates
Recently added Catalysts
ACAD Positive Sentiment

Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Acadia Pharmaceuticals reported Q3 2026 revenues of $342 million, driven by strong commercial momentum for DAYBUE and NUPLAZID. CEO Catherine Owen Adams highlighted significant uptake of DAYBUE STIX in the U.S. market. The company also noted continued growth in Europe for its portfolio.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenues reached $342 million.
  • Strong commercial momentum for DAYBUE and NUPLAZID.
  • DAYBUE STIX saw meaningful uptake in the U.S.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
6.4%
average across 10 past catalysts
Lead asset
ACP-211
Phase 2 · Major Depressive Disorder (MDD)

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. “Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build m

Frequently Asked Questions

What were Acadia's total revenues for Q3 2026?

Acadia reported total revenues of $342 million for Q3 2026.

What products contributed to Acadia's revenue growth?

DAYBUE and NUPLAZID contributed to Acadia's revenue growth.

How did DAYBUE perform in the U.S. market?

DAYBUE experienced strong commercial momentum and uptake in the U.S.

Who is the CEO of Acadia Pharmaceuticals?

Catherine Owen Adams is the CEO of Acadia Pharmaceuticals.

ShareAdd on Google
Tags: ACAD Acadia Pharmaceuticals Q3 2026 DAYBUE NUPLAZID financial results
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$956M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ACP-211Phase 2
Major Depressive Disorder (MDD) →

Catalyst track record

+24%
best trade around ACAD's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for ACAD.

See every catalyst's timing & PoA →